The HSP90AB1 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line, engineered for the disruption of the HSP90AB1 gene. This product provides a heterogeneous population of cells carrying targeted modifications at the HSP90AB1 locus, enabling loss-of-function studies without the clonal selection bias inherent in single-cell-derived knockout lines. The polyclonal format captures a range of editing outcomes, offering a robust cellular model for investigating HSP90AB1-dependent biology in a gastric cancer context.
The AGS parental line is a widely characterized epithelial cell line originated from a gastric adenocarcinoma patient, serving as a standard model for studying gastric adenocarcinoma pathobiology. These cells exhibit features of poorly differentiated gastric carcinoma, including dysregulated signaling pathways and aggressive growth phenotypes. Their human origin and adherent growth properties make them well-suited for in vitro cancer research, particularly for exploring molecular mechanisms governing tumor cell proliferation, survival, and migration.
HSP90AB1 encodes a constitutively expressed member of the HSP90 family of molecular chaperones, which functions in an ATP-dependent manner to stabilize and properly fold a repertoire of client proteins. Key clientele include the serine/threonine kinase AKT, the epidermal growth factor receptor EGFR, human epidermal growth factor receptor 2 HER2, cyclin-dependent kinase CDK4, hypoxia-inducible factor HIF1A, and the serine/threonine kinase RAF1. In complex with co-chaperones such as CDC37, AHA1, p23, Hop, HSP70, and HSP40, HSP90AB1 facilitates the maturation and activity of these clients, thereby sustaining pivotal oncogenic signaling modules including the PI3K/AKT/mTOR cascade and the RAS/RAF/MEK/ERK pathway. Upstream, HSP90AB1 is transcriptionally activated by heat shock factor 1 HSF1 in response to cellular stress and is post-translationally regulated by AKT-mediated phosphorylation and by the deacetylase SIRT1. Disruption of HSP90AB1 thus leads to proteasomal degradation of its client proteins, abrogating downstream signal transduction.
In AGS cells, HSP90AB1 is integral to the maintenance of malignant properties, as it supports the stability of growth factor receptors and downstream effectors that drive proliferation and survival. Knockout of HSP90AB1 in this gastric adenocarcinoma model creates a genetically defined tool for dissecting chaperone dependency in gastric oncogenesis. The resulting perturbation of chaperone-client networks is expected to suppress PI3K/AKT and MAPK/ERK signaling, induce cell cycle arrest at G1 via destabilization of CDK4/cyclin D complexes, and promote apoptotic susceptibility. This cellular context is particularly relevant for investigating HSP90-dependent mechanisms in gastric adenocarcinoma and for evaluating the therapeutic potential of HSP90 inhibition.
This polyclonal knockout population is ideally suited for a range of downstream applications in cancer biology and drug discovery. Researchers can employ it for quantitative immunoblotting to profile client protein degradation (e.g., AKT, EGFR, HER2) following HSP90AB1 disruption, for co-immunoprecipitation studies to examine chaperone-client interactions, and for functional assays including MTT viability assays, Annexin V apoptosis assays, cell cycle analysis by flow cytometry, and transwell migration assays. Transcriptomic analyses via RT-qPCR enable monitoring of transcriptional changes in client genes and pathway components. The model also serves as a platform for validating HSP90 inhibitors and for combination drug screens targeting parallel survival pathways. For further information and technical support, please contact Ascent Research.
